Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, has granted stock options and restricted stock units to a newly hired employee. The company issued non-statutory stock options to purchase 21,500 ordinary shares and restricted stock units for 11,500 ordinary shares. These grants were made under Mural's 2024 Inducement Stock Option and Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $3.16 per share, equal to the closing price on September 3, 2024. They have a ten-year term and vest over four years, with 25% vesting after one year and 6.25% quarterly thereafter. The restricted stock units also vest over four years, with 25% vesting annually. Both grants are subject to continued employment and specific award agreements.
Mural Oncology plc (Nasdaq: MURA), una società di immuno-oncologia in fase clinica, ha concesso opzioni su azioni e unità di azioni vincolate a un nuovo dipendente. L'azienda ha emesso opzioni su azioni non statutarie per acquistare 21.500 azioni ordinarie e unità di azioni vincolate per 11.500 azioni ordinarie. Queste concessioni sono state effettuate nell'ambito del Piano di Incentivazione e di Opzione su Azioni del 2024 di Mural, in conformità con la Regola di Quotazione 5635(c)(4) di Nasdaq.
Le opzioni su azioni hanno un prezzo di esercizio di $3.16 per azione, pari al prezzo di chiusura del 3 settembre 2024. Hanno una durata di dieci anni e maturano in quattro anni, con il 25% che matura dopo un anno e il 6,25% trimestralmente successivamente. Anche le unità di azioni vincolate maturano in quattro anni, con il 25% che matura annualmente. Entrambi i concedimenti sono soggetti a continuare l'impiego e a specifici accordi di assegnazione.
Mural Oncology plc (Nasdaq: MURA), una empresa de inmuno-oncología en etapa clínica, ha otorgado opciones sobre acciones y unidades de acciones restringidas a un nuevo empleado. La compañía emitió opciones sobre acciones no estatutarias para comprar 21,500 acciones ordinarias y unidades de acciones restringidas para 11,500 acciones ordinarias. Estas concesiones se realizaron bajo el Plan de Incentivos y Opciones sobre Acciones de 2024 de Mural, cumpliendo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Las opciones sobre acciones tienen un precio de ejercicio de $3.16 por acción, igual al precio de cierre del 3 de septiembre de 2024. Tienen un plazo de diez años y se consolidan durante cuatro años, con el 25% consolidándose después de un año y el 6.25% trimestralmente a partir de entonces. Las unidades de acciones restringidas también se consolidan durante cuatro años, con el 25% consolidándose anualmente. Ambas concesiones están sujetas a la continuidad del empleo y a acuerdos específicos de asignación.
Mural Oncology plc (Nasdaq: MURA)는 임상 단계의 면역 항암제 회사로, 신입 직원에게 주식 옵션과 제한 주식 단위를 부여했습니다. 회사는 21,500주 보통주를 매입할 수 있는 비법적 주식 옵션과 11,500주 보통주에 대한 제한 주식 단위를 발행했습니다. 이러한 부여는 Mural의 2024 유인 주식 옵션 및 인센티브 계획에 따라 이루어졌으며, Nasdaq 상장 규정 5635(c)(4)를 준수합니다.
주식 옵션의 행사가격은 $3.16로, 2024년 9월 3일 종가와 동일합니다. 이 옵션은 10년의 기간을 가지며 4년에 걸쳐 분할되어, 1년 후에 25%가 발생하고 그 이후로는 분기마다 6.25%가 발생합니다. 제한 주식 단위도 4년에 걸쳐 발생하며, 매년 25%가 발생합니다. 두 가지 부여는 고용 지속성과 특정 상여 계약에 따라 달라집니다.
Mural Oncology plc (Nasdaq: MURA), une société d'immuno-oncologie en phase clinique, a accordé des options d'achat d'actions et des unités d'actions restreintes à un nouvel employé. La société a émis des options d'achat d'actions non statutaires pour l'achat de 21 500 actions ordinaires et des unités d'actions restreintes pour 11 500 actions ordinaires. Ces attributions ont été effectuées dans le cadre du Plan de Stock Options d'Incitation de Mural 2024, en conformité avec la Règle de Cotation 5635(c)(4) de Nasdaq.
Les options d'achat d'actions ont un prix d'exercice de $3.16 par action, égal au prix de clôture du 3 septembre 2024. Elles ont une durée de dix ans et se débloquent sur quatre ans, avec 25 % se déverrouillant après un an et 6,25 % chaque trimestre par la suite. Les unités d'actions restreintes se débloquent également sur quatre ans, avec 25 % se déverrouillant annuellement. Les deux attributions sont soumises à la condition d'un emploi continu et à des accords spécifiques d'attribution.
Mural Oncology plc (Nasdaq: MURA), ein Unternehmen für immunonkologische Therapien in der klinischen Phase, hat einem neuangestellten Mitarbeiter Aktienoptionen und beschränkte Aktieneinheiten gewährt. Das Unternehmen hat nicht-statutäre Aktienoptionen zur Erfassung von 21.500 Stammaktien und beschränkte Aktieneinheiten für 11.500 Stammaktien ausgegeben. Diese Gewährungen erfolgten im Rahmen des Mural 2024 Incentive- und Aktienoptionsplans, in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4).
Die Aktienoptionen haben einen Ausübungspreis von $3.16 pro Aktie, was dem Schlusskurs vom 3. September 2024 entspricht. Sie haben eine Laufzeit von zehn Jahren und werden über vier Jahre hinweg fällig, wobei 25% nach einem Jahr und danach vierteljährlich 6,25% fällig werden. Auch die beschränkten Aktieneinheiten werden über vier Jahre fällig, mit jährlich 25% die fällig werden. Beide Gewährungen unterliegen dem fortgesetzten Beschäftigungsverhältnis und spezifischen Zuteilungsvereinbarungen.
- Mural Oncology is attracting new talent with competitive stock-based compensation
- The company is complying with Nasdaq listing rules for inducement grants
- None.
WALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on September 3, the Company granted to one newly hired employee (i) non-statutory stock options to purchase an aggregate of 21,500 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 11,500 ordinary shares of the Company, pursuant to the Company’s 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.
Contact
Katie Sullivan
katie.sullivan@muraloncology.com
FAQ
What stock options did Mural Oncology (MURA) grant to its new employee on September 3, 2024?
How many restricted stock units did Mural Oncology (MURA) issue to the new employee?
What is the vesting schedule for the stock options granted by Mural Oncology (MURA)?
Under which plan were the inducement grants made by Mural Oncology (MURA)?
